Patient-centered cancer treatment center
Hong Kong United Oncology Centre (HKUOC)
Hong Kong United Oncology Centre (HKUOC) is a Hong Kong-based cancer treatment center that provides cancer-related medical services, including cancer screening, cancer diagnosis, and cancer treatment. Led by experienced Hong Kong oncologists, it delivers cutting-edge cancer care, such as immunotherapy, chemotherapy, targeted drug therapy, radiotherapy (radiation therapy), hormone therapy, and palliative care.
As a patient-centered Hong Kong oncology center,we set up dedicated WhatsApp groups for active-treatment patients to connect with their attending physicians.. This allows close monitoring of patients’ conditions, enabling contact with attending physicians even outside office hours for more effective disease follow-up. We also offer patients drug assistance programs and clinical research programs, aiming to alleviate their financial burden.
As a professional Hong Kong cancer treatment center, our mission is to act with empathy and put patients first. Our clinical oncologists provide professional medical advice and appropriate treatment plans. We care about patients’ needs,tailoring the most personalized treatment for each individual,and offer a comfortable treatment environment. We strive to ensure patients receive sufficient support throughout their cancer-fighting and recovery journey, empowering them to actively combat the disease.
Hong Kong Oncologists
Dr. Li Yu Chung, Jacky
Dr. Li Yu Chung, Jacky
Clinical Oncology Specialist
- Bachelor of Medicine and Surgeon General Practice (MBBS) from the University of Hong Kong
- Fellow of The Royal College of Radiologists (UK) FRCR (UK)
- FHKCR (Hong Kong College of Radiology)
- Fellow of the Hong Kong Academy of Medicine (Radiology) FHKAM
New Book Recommendation by Dr. Li Yu Chung, Jacky
《50 Advanced Lung Cancer Treatment Practical Strategies 》
Written by Dr. Li Yu Chung, Jacky, Specialist in Clinical Oncology, Hong Kong
Synopsis: Lung cancer is not only one of the top ten most common cancers in Hong Kong, but it has also been the leading cause of cancer death in the city over the past few decades. The vast amount of information available online can be overwhelming for patients and their families, and may not even be applicable to the local healthcare environment.
As a seasoned clinical oncologist based in Hong Kong, Dr. Li Yu Chung, Jacky, observed that most medical information on lung cancer available to the public lacks practicality and targeted relevance. He thus wrote this book, carefully curating topics and compiling practical knowledge to equip patients with a clear understanding of their condition during their cancer fight, with the aim of helping them access the most suitable and personalized treatment plans.
Each chapter of the new book 50 Advanced Practical Strategies for Lung Cancer Treatment is crafted by Dr. Li Yu Chung, Jacky, a Hong Kong-based oncologist, based on specific or special scenarios encountered in lung cancer management. Dr. Li skillfully adopts a real-world perspective to focus on researching the most common and up-to-date clinical issues related to lung cancer diagnosis and treatment. These 50 invaluable clinical tips will provide practical knowledge and serve as a guiding resource for the general public, especially lung cancer patients and their family members.
About Us
Hong Kong United Oncology Centre (HKUOC)
Hong Kong’s Professional Cancer Treatment Center
As a professional Hong Kong cancer treatment center, Hong Kong United Oncology Centre starts with empathy and puts patients first. Composed of senior clinical oncologists and a professional nursing team, we strive to tailor personalized treatment for cancer patients, providing professional medical advice and appropriate cancer treatment plans.
Learn About Common Cancer Treatment Plans
Hong Kong United Oncology Centre offers a diverse range of cancer treatment plans. Our professional Hong Kong oncologists will provide you with the most suitable cancer treatment program.
Understanding the Common Types of Cancer in Hong Kong
Personalized treatment plans are provided by experienced clinical oncologists, including immunotherapy, targeted therapy, and chemotherapy.
Lung cancer
Hong Kong’s top cancer killer; we offer EGFR/ALK genetic testing, early treatment, targeted therapy, immunotherapy, and the latest targeted drug treatments.
liver cancer
We provide diverse solutions including colonoscopy, minimally invasive surgery, CEA monitoring, and HIFU.
colorectal cancer
We offer RAS/MSI-H genetic testing, early follow-up, survival rate assessment, HER2 targeted therapy, and chemotherapy regimens for triple-negative breast cancer.
breast cancer
The most common cancer among Hong Kong women; we provide BRCA genetic testing, HER2 targeted therapy, and chemotherapy regimens for triple-negative breast cancer.
Cancer Clinical Research
Providing medical research on therapeutic drugs for cancers such as lung cancer and breast cancer
Ongoing
Lung cancer
Ongoing
Lung cancer
Ongoing
Lung cancer
Ongoing
breast cancer
FAQ
How can cancer patients stay in touch with their attending physician?
The Hong Kong Joint Cancer Centre has established a dedicated WhatsApp group for patients undergoing treatment, facilitating close communication between patients and attending doctors, and enabling follow-up even during non office hours.
What cancer treatment options does the Cancer Center offer?
The center provides a variety of professional cancer treatment methods including immunotherapy, chemotherapy, targeted therapy, radiation therapy, hormone therapy, and palliative therapy. Our Hong Kong clinical oncologists will recommend the most suitable treatment plan for the patient's condition.
Do you have any preferential or subsidy plans if the economic burden of treatment on patients is heavy?
The Hong Kong Joint Cancer Centre provides drug sponsorship and clinical research programs to alleviate the financial burden on patients in need.
Cancer drugs
Latest news research
NCT06899126: Destiny-lung 06 Research
The Hong Kong United Oncology Centre is currently conducting an international Phase III clinical trial. If you are a patient with locally advanced, unresectable, or metastatic HER2-overexpressing non-squamous non-small cell lung cancer with PD-L1 TPS < 50%, please contact us. We will conduct an initial assessment to determine your eligibility for this clinical trial. Medication and imaging scans are free. However, patients must understand the purpose of the study and any potential risks.
Tovorafenib approved by the FDA: breakthrough treatment for low-grade glioma in children with BRAF mutation
The FDA accelerated the approval of Tovorafenib (Ojemda) for the treatment of low-grade gliomas in children with recurrent or refractory BRAF variants on April 23, 2024. This article introduces its efficacy data, safety characteristics and clinical application guidelines in detail. It is suitable for reference by parents and medical staff who are concerned about the treatment of brain tumors in children. Learn more about the latest information about this breakthrough targeted therapy.
A new generation of Menin inhibitors revolutionizes the treatment of acute leukemia, giving Hong Kong patients new hope
The 2024 Annual meeting of the American Society of Hematology will reveal the safety and efficacy of a new generation of Menin inhibitors in the treatment of acute myeloid leukemia (AML). Drugs such as Ziftomenib and Bleximenib showed significant complete remission rates for KMT2A rearrangement and NPM1 mutations, bringing new hope to patients in Hong Kong. Learn more about clinical trial data and treatment prospects.
Retifanlimab-dlwr is used to treat metastatic or recurrent locally advanced Merkel cell carcinoma
The U.S. FDA accelerated the approval of the PD-1 antibody retifanlimab-dlwr for the treatment of metastatic or recurrent locally advanced Merkel cell carcinoma in March 2023. The POD1UM-201 clinical trial showed a 52% objective remission rate, bringing new treatment options to patients with this rare skin cancer. Understand medication recommendations, safety data, and treatment precautions.
Zenocutuzumab: FDA approves new bispecific antibody for the treatment of NRG1 gene fusion cancer
Zenocutuzumab was approved by the U.S. FDA for the treatment of patients with lung cancer and pancreatic cancer with NRG1 gene fusion, marking a breakthrough in cancer treatment.
The U.S. Food and Drug Administration (FDA) approved the IDH1/2 inhibitor Vorasidenib for patients with specific astrocytoma or oligodendrocytoma
The U.S. FDA approved the IDH1/2 inhibitor Vorasidenib for use in patients with specific astrocytoma and oligodendrocytoma in August 2024. The INDIGO clinical trial has shown that it significantly prolongs the survival period without progress, bringing new treatment options to patients with IDH mutant glioma. Learn about applicable patients, medication recommendations, and safety information.
